A. Kasmia, M.Sc., M.D. Baldwin Neurology, LLC, 188 Hospital drive Suite 300, Fairhope, Al 36532. Phone (251)-990-1910, Fax (251)-990-1911 |
Neurology news
|
MULTIPLE SCLEROSIS
Arbaclofen placarbil (AP): May be effective in reducing spasticity with fewer doses. The ongoing study is funded by XenoPort, Inc. Link: http://www.xenoport.com/research_development/ap.htm
Phase 3 Trial for Alemtuzumab Phase 3 trial of Alemtuzumab versus interferon beata-1a seems to be positive with significant reduction in relapses in patients taking this agent versus Rebif. Comparison of Alemtuzumab and Rebif Efficacy in Multiple Sclerosis I (CARE-MS I) trial were presented at the 5th Joint Triennial Congress of the European and Americas Committees for Treatment and Research in Multiple Sclerosis (ECTRIMS/ACTRIMS). This substance helps block the effect and number of two blood cell types called the monocytes and lymphocytes thereby reducing multiple sclerosis attacks.
|